For many in the longevity community, the six-month mark is the "Gold Standard" milestone. It is the point where the initial placebo effects fade, and the real biological data—from lipid panels to biological age clocks—begins to tell a definitive story. While clinical trials like the ERAP trial for Alzheimer’s and the Kraig et al. study…

For many people interested in living longer, the goal is simple: avoid the "Big Four" diseases of aging. At the top of that list is cancer. Modern science is moving away from just treating cancer after it appears and toward Rapamycin and cancer prevention as a way to stop the disease before it even starts.…

Rapamycin and Metabolic Effects: Blood Sugar, Cholesterol, and What to Monitor The pursuit of human longevity has transitioned from speculative "elixirs" to the rigorous science of geroprotection, with the mechanistic target of rapamycin (mTOR) pathway serving as a central hub. While Rapamycin is the most robust pharmacological intervention for extending lifespan in model organisms, its…

Navigating the landscape of geroprotectors requires a shift from traditional disease treatment to proactive biological optimization. Rapamycin dosing for longevity has moved beyond theoretical mouse models and into the clinics of specialty practitioners, yet the transition from a daily transplant drug to an intermittent anti-aging protocol requires precision to maximize autophagy while avoiding metabolic pitfalls.…

For decades, the search for a true "longevity pill" was considered more science fiction than science. However, the discovery of the mTOR pathway and its inhibition by a soil-derived molecule called rapamycin has shifted that perspective. While animal studies have long shown that rapamycin can extend lifespan by up to 60%, the question of whether…